Loncar Investments Selects Cancer Research Institute as Exclusive Charitable Partner in Immunotherapy Research Donation Program
December 01 2015 - 9:50AM
Business Wire
On Giving Tuesday, Loncar Investments and the Cancer Research
Institute (CRI) announced that they have entered into an exclusive
charitable partnership for the Loncar Cancer Immunotherapy ETF
(ticker: CNCR). Loncar Investments will use royalties it receives
as the exchange-traded fund’s index provider to donate regular
contributions to CRI that amount to 4 basis points, or 0.04%, of
CNCR’s total assets.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151201005192/en/
“Today’s breakthroughs in cancer immunotherapy have emerged from
decades of basic scientific research funded by visionary
benefactors, with the Cancer Research Institute at the forefront,”
said Brad Loncar, CEO of Loncar Investments. “As our index supports
public companies delivering these advances to patients, we want to
foster that critical early research as well. There is no better way
to do that than to give to an immunotherapy pioneer like CRI.”
“The Cancer Research Institute is pleased to be the recipient of
Loncar Investments’ charitable giving program,” said Jill
O’Donnell-Tormey, Ph.D, CEO and Director of Scientific Affairs at
CRI. “Our mission is to fuel the discovery and development of
immunotherapies for all forms of cancer, and we are delighted by
how the fund generates awareness of the area.”
Founded in 1953, the Cancer Research Institute is the world’s
only non-profit organization dedicated to harnessing immunotherapy
to conquer cancer.
The partnership is a two-year agreement, with an option for
renewal in 2017. Loncar Investments has guaranteed a minimum
donation of at least $20,000 per calendar year.
About Cancer Research Institute
The Cancer Research Institute (CRI), established in 1953, is the
world’s only nonprofit organization dedicated exclusively to
transforming cancer patient care by advancing scientific efforts to
develop new and effective immune system-based strategies to
prevent, diagnose, treat, and eventually cure all cancers. Guided
by a world-renowned Scientific Advisory Council that includes three
Nobel laureates and 27 members of the National Academy of Sciences,
CRI has invested $311 million in support of research conducted by
immunologists and tumor immunologists at the world’s leading
medical centers and universities, and has contributed to many of
the key scientific advances that demonstrate the potential for
immunotherapy to change the face of cancer treatment. To learn
more, go to www.cancerresearch.org.
About Loncar Investments: Loncar Investments, LLC, the
provider of the Loncar Immunotherapy Index, is committed to making
the biotechnology space more approachable to a wider range of
investors. The company is principally owned by biotech investor
Brad Loncar.
For more information, follow LoncarFunds on Twitter at
@LoncarFunds.
The Funds investment objectives, risks, charges and expenses
must be considered carefully before investing. The summary and
statutory prospectuses contain this and other important information
about the investment company, and may be obtained by calling
800.617.0004 or visiting www.loncarfunds.com. Read it carefully
before investing.
Investing involves risk; Principal loss is possible.
The Loncar Cancer Immunotherapy ETF is distributed by Quasar
Distributors, LLC.
A basis point is a common unit of measure for interest rates and
other percentages in finance. One basis point is equal to 1/100th
of 1%, or 0.01% (0.0001).
The Loncar Cancer Immunotherapy Index is an index of 30
securities that have a strategic focus on the area of cancer
immunotherapy, or harnessing the immune system to fight cancer.
Quotes for the index can be found under the symbol “LCINDX” on the
Bloomberg Professional service and other financial data
providers.
One may not directly invest in an index.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151201005192/en/
Lauren Davis for ISE ETF
Ventures610-228-2103ise@gregoryfca.com
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From Sep 2023 to Sep 2024